

Prevention of Preterm Birth in Multifetal Gestation

Release Date: April 27, 2020

Expiration Date: April 26, 2022

Content was originally presented at OB Challenges – Expecting the Unexpected on May 18, 2019.

Accreditations

The MEDNAX Center for Research, Education, Quality and Safety is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The MEDNAX Center for Research, Education, Quality and Safety designates this Internet Enduring Material for a maximum of 0.75 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The MEDNAX Center for Research, Education, Quality and Safety is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. (#PO258)

The MEDNAX Center for Research, Education, Quality and Safety designates this enduring activity for a maximum of 0.75 *nursing contact hour(s)*. Participants should only claim credit commensurate with the extent of their participation in the activity.

Enduring Material - The ACCME recognizes this educational activity as an enduring material. The estimated time for completion of this enduring material is 45 minutes. This presentation was released on April 27, 2020. The expiration date of this enduring material is April 26, 2022.

The ANCC recognizes this educational activity as an enduring material. The estimated time for completion of this enduring material is 45 minutes. This presentation was released on April 27, 2020. The expiration date of this enduring material is April 26, 2022.

Target Audience - This presentation is intended for physicians, advanced practice providers, and other clinicians.

Purpose – Multifetal pregnancies are at high risk for preterm birth. Several strategies have been tried to reduce that risk, however, most are ineffective for uncomplicated multifetal pregnancy. Vaginal progesterone and cervical pessary appear promising for twin pregnancies with short cervical length.

CME- ACGME/ABMS Competencies addressed in this educational activity include Patient Care and Procedural Skills and Practice-Based Learning and Improvement.

CNE- IOM Competencies addressed in this educational activity include: Employ evidence-based practice.

Desired Learning Outcome - Clinicians will be able to discuss the advantages and disadvantages of vaginal progesterone, pessary, and cerclage for women with twin pregnancy and short cervix. Clinicians will implement at least one change in practice to reduce the risk of preterm birth.

Disclosures of Financial Relationships and Resolution of Conflicts of Interest is designed to ensure quality, objective, balanced, and scientifically rigorous continuing education activities. All individuals in a position to influence and/or control the content of continuing education activities have been asked to disclose all relevant financial relationships within the past 12 months. Any real or apparent conflicts of interest related to the content of the faculty's presentation have been resolved as have any real or apparent conflicts of interest by the planners as related to the content of this conference. Beyond disclosure of relevant financial relationships, faculty are required to disclose when they plan to discuss pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical. The MEDNAX Center for Research, Education, Quality and Safety is committed to providing learners with commercially unbiased continuing education activities.

Faculty, Planners and Reviewer Disclosures

C Andrew Combs, MD, PhD – Perinatologist, Obstetrix Medical Group, San Jose, CA; Associate Director of Quality for MFM, Obstetrix, MEDNAX National Medical Group, Sunrise, FL

No relevant financial relationships or conflicts of interest to disclose. FDA Disclosure: Arabin Pessary: Non-Approved device-Off-Label Use; Micronized Progesterone (vaginal or oral): Off-label use; Cervical Pessary (US brands): Off-label use; Betamethasone: Off-label use.

Nicole Brenson, MEd – Operations Manager, The MEDNAX Center for Research, Education, Quality and Safety, Sunrise, FL

No relevant financial relationships or conflicts of interest to disclose.

Hilja Dodd Sousa Conceição, CHCP, CPHQ – CME Program Manager, The MEDNAX Center for Research, Education, Quality and Safety, Sunrise, FL

No relevant financial relationships or conflicts of interest to disclose.

Kassandra S. Greci, DNP, APRN, WHNP-BC – Manager, Professional Nursing Education, The MEDNAX Center for Research, Education, Quality and Safety, Sunrise, FL

No relevant financial relationships or conflicts of interest to disclose.

Commercial Support - There is no commercial support for this educational activity. Please note that the content of this educational activity was originally presented at a live conference (OB Challenges – Expecting the Unexpected) on May 18, 2019.

Participation and Contact hour(s) - Participants are expected to review all content in the video, access reference materials as needed for additional self-directed learning, take and score 70% or greater correct on the post test, and complete the evaluation in order to earn *AMA PRA Category 1 Credit(s)[™]* and/or *nursing contact hour(s)*.

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of credit for this activity, please consult your professional licensing board.

Contact - Should you have any questions or concerns, please contact us at continuing_education@mednax.com